Sparsentan

Molecular mass: 592.76 g/mol  PubChem compound: 10257882

Therapeutic indications

Sparsentan is indicated for:

Primary immunoglobulin A nephropathy with a urine protein excretion ≥1.0 g/day

Population group: only adults (18 years old or older)

Sparsentan is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Sparsentan is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Angiotensin receptor blockers, endothelin receptor antagonists, renin inhibitors

at least one of
Angiotensin II antagonists, plain
Aliskiren
Endothelin receptor antagonists

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: FILSPARI Film-coated tablet
Structured Product Labeling (SPL/PLR) 2023: FILSPARI Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈